坐标化病灶位置分析提升基于ROI的脑胶质瘤影像组学诊断
本研究基于三个中心679例胶质瘤患者的术前增强T1WI和T2WI MR图像,构建融合坐标化病灶位置分析与ROI影像组学的模型,用于预测肿瘤分级、IDH状态和总生存期。融合模型在分级、IDH和OS预测上的平均AUC分别为0.756、0.748和0.768,均高于单纯影像组学模型和位置模型,且泛化性能更优(中位ΔACC -0.125 vs -0.200,p=0.018)。结论认为坐标化病灶位置分析可提升基于ROI的影像组学诊断的准确性和泛化能力。
要点
- 融合病灶位置与影像组学可提高胶质瘤分级、IDH状态和OS预测的AUC。
- 融合模型跨中心泛化性能优于单纯影像组学模型(ΔACC更小,p=0.018)。
- 阅片时可结合肿瘤解剖位置分布模式辅助病理和临床特征预测。
核心结论
- 坐标化病灶位置分析通过整合肿瘤空间位置信息,可提升基于ROI的影像组学模型对胶质瘤分级、IDH状态和OS预测的准确性和泛化性能。
研究设计与样本
- 回顾性研究,纳入三个中心(Jinling Hospital、Tiantan Hospital、Cancer Genome Atlas Program)共679例胶质瘤患者,平均年龄50岁±14,男性388例。
- 使用术前增强T1加权和T2加权MR图像,基于坐标化病灶位置分析和ROI影像组学构建融合位置-影像组学模型。
- 采用跨中心交叉验证策略,以AUC和ΔACC(测试集ACC-训练集ACC)评估模型准确性和泛化性能,用DeLong检验和Wilcoxon符号秩检验比较模型间诊断性能。
诊断标准与关键数值
- 融合位置-影像组学模型预测分级、IDH状态和OS的平均AUC分别为0.756、0.748和0.768。
- 单纯影像组学模型对应平均AUC分别为0.731、0.686和0.716;单纯位置模型分别为0.706、0.712和0.740。
- 融合模型中位ΔACC为-0.125(四分位距0.130),影像组学模型为-0.200(四分位距0.195),差异p=0.018。
临床应用与阅片要点
- 在胶质瘤MRI阅片和报告时,可关注肿瘤解剖位置分布模式,将其作为辅助信息与ROI影像组学特征结合,以提高分级、IDH状态和OS预测的准确性。
- 跨中心应用时,融合位置信息的模型泛化性能更稳定,可减少因设备或中心差异导致的性能下降。
局限性
- 原文未明确列出研究局限性;但作为回顾性研究,可能存在选择偏倚。
- 研究基于三个中心数据,外部推广至更多中心或不同扫描协议时需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the value of coordinatized lesion location analysis (CLLA), in empowering ROI-based imaging diagnosis of gliomas by improving accuracy and generalization performances.
METHODS: In this retrospective study, pre-operative contrasted T1-weighted and T2-weighted MR images were obtained from patients with gliomas from three centers: Jinling Hospital, Tiantan Hospital, and the Cancer Genome Atlas Program. Based on CLLA and ROI-based radiomic analyses, a fusion location-radiomics model was constructed to predict tumor grades, isocitrate dehydrogenase (IDH) status, and overall survival (OS). An inter-site cross-validation strategy was used for assessing the performances of the fusion model on accuracy and generalization with the value of area under the curve (AUC) and delta accuracy (ACC) (ACCtesting-ACCtraining). Comparisons of diagnostic performances were performed between the fusion model and the other two models constructed with location and radiomics analysis using DeLong's test and Wilcoxon signed ranks test.
RESULTS: A total of 679 patients (mean age, 50 years ± 14 [standard deviation]; 388 men) were enrolled. Based on tumor location probabilistic maps, fusion location-radiomics models (averaged AUC values of grade/IDH/OS: 0.756/0.748/0.768) showed the highest accuracy in contrast to radiomics models (0.731/0.686/0.716) and location models (0.706/0.712/0.740). Notably, fusion models ([median Delta ACC: - 0.125, interquartile range: 0.130]) demonstrated improved generalization than that of radiomics model ([- 0.200, 0.195], p = 0.018).
CONCLUSIONS: CLLA could empower ROI-based radiomics diagnosis of gliomas by improving the accuracy and generalization of the models.
CLINICAL RELEVANCE STATEMENT: This study proposed a coordinatized lesion location analysis for glioma diagnosis, which could improve the performances of the conventional ROI-based radiomics model in accuracy and generalization.
KEY POINTS: • Using coordinatized lesion location analysis, we mapped anatomic distribution patterns of gliomas with specific pathological and clinical features and constructed glioma prediction models. • We integrated coordinatized lesion location analysis into ROI-based analysis of radiomics to propose new fusion location-radiomics models. • Fusion location-radiomics models, with the advantages of being less influenced by variabilities, improved accuracy, and generalization performances of ROI-based radiomics models on predicting the diagnosis of gliomas.
引用
- Liu, Zhang, Li, et al. Coordinatized lesion location analysis empowering ROI-based radiomics diagnosis on brain gliomas. Eur Radiol. 2023. PMID: 37382614. doi:10.1007/s00330-023-09871-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。